UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver

Gut, 2002-01, Vol.50 (1), p.106-110

2002

Volltextzugriff (PDF)

P1137 TREATMENT OF CHRONIC HCV GENOTYPE 1 (G1) INFECTION WITH BOCEPREVIR IN GERMAN REAL-LIFE: HIGH EFFICACY TOGETHER WITH MODERATE TREATMENT DISCONTINUATION RATES IN TREATMENT-NAIVE PATIENTS

Journal of hepatology, 2014-04, Vol.60 (1), p.S461-S461

2014

Volltextzugriff (PDF)

912 LEUKOCYTE DECLINE PREDICTS SUSTAINED VIROLOGIC RESPONSE IN PATIENTS UNDERGOING PEGINTERFERON alfa-2b/RIBAVIRIN TREATMENT OF CHRONIC HCV GENOTYPE 1 INFECTION

Journal of hepatology, 2013-04, Vol.58, p.S376-S376

2013

Volltextzugriff (PDF)

797 HIGH PREVALENCE OF CHRONIC HEPATITIS C IN 8009 PATIENTS WITH MIGRATION BACKGROUND LIVING IN GERMANY

Journal of hepatology, 2013-04, Vol.58, p.S325-S325

2013

Volltextzugriff (PDF)

1164 HEMOGLOBINE DECLINE DURING PEGINTERFERON ALFA-2B/RIBAVIRIN TREATMENT IN REAL-LIFE IS ASSOCIATED WITH FAVORABLE SVR RATES IN DIFFICULT-TO-TREAT PATIENTS WITH HCV GENOTYPE 1 INFECTION

Journal of hepatology, 2012-04, Vol.56, p.S460-S461

2012

Volltextzugriff (PDF)

1140 THYROID DYSFUNCTION INDUCED BY PEGINTERFERON ALFA-2B (PEG-2B)/RIBAVIRIN (RBV) IS A FAVORABLE PREDICTOR OF SVR IN DIFFICULT-TO-TREAT PATIENTS WITH HCV GENOTYPE 1 (G1) INFECTION

Journal of hepatology, 2012-04, Vol.56, p.S450-S450

2012

Volltextzugriff (PDF)

435 TREATMENT OF HCV GENOTYPE 3 (GT3)-INFECTION WITH PEG-IFN A-2B AND RIBAVIRIN (RBV): AGE RELATED DIFFERENCES IN SVR AND RELAPSE

Journal of hepatology, 2011-03, Vol.54, p.S177-S177

2011

Volltextzugriff (PDF)

Glutathione protects the rat liver against reperfusion injury after hypothermic preservation

Gastroenterology (New York, N.Y. 1943), 1999-07, Vol.117 (1), p.200-210

1999

Volltextzugriff (PDF)

305 TREATMENT-INDUCED ANEMIA PREDICTS SVR AMONG ALL HCV-GENOTYPES TREATED WITH PEG-IFNα-2B AND RIBAVIRIN: MARKED DIFFERENCES BETWEEN FEMALE AND MALE

Journal of hepatology, 2010, Vol.52, p.S128-S128

2010

Volltextzugriff (PDF)

GSH Attenuates Organ Injury and Improves Function after Transplantation of Fatty Livers

European surgical research, 2010-01, Vol.45 (1), p.13-19

2010

Volltextzugriff (PDF)

[677] CHOLESTASIS BUT NOT STEATOSIS POTENTIATES LIVER INJURY BY ACTIVATED KUPFFER CELLS: EVIDENCE FOR A ROLE FOR CYCLOOXYGENASE-2

Journal of hepatology, 2007-04, Vol.46, p.S256-S256

2007

Volltextzugriff (PDF)

Utilization of elbasvir/grazoprevir (EBR/GZR) and adoption of resistance associated substitutions (RAS) testing in real-world treatment of HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R)

Journal of hepatology, 2018-04, Vol.68, p.S272-S273

2018

Volltextzugriff (PDF)

THU-321 - Utilization of elbasvir/grazoprevir (EBR/GZR) and adoption of resistance associated substitutions (RAS) testing in real-world treatment of HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R)

Journal of hepatology, 2018-04, Vol.68, p.S272-S273

2018

Volltextzugriff (PDF)

Gender-dependent differences in the efficacy and safety of Boceprevir triple therapy in German real-life

Zeitschrift für Gastroenterologie, 2015-08, Vol.53 (8)

2015

Volltextzugriff (PDF)

Preservation injury of the liver : mechanisms and novel therapeutic strategies

Journal of hepatology, 2000-03, Vol.32 (3), p.508-515

2000

Volltextzugriff (PDF)

Inverse correlation of serum bilirubin and alkaline phosphatase in fulminant Wilson's disease

Journal of hepatology, 1998-10, Vol.29 (4), p.683-683

1998

Volltextzugriff (PDF)

Glutathione protects the rat liver against reperfusion injury after prolonged warm ischemia

Annals of surgery, 2004-02, Vol.239 (2), p.220-231

2004

Volltextzugriff (PDF)

Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C–dependent mechanisms in cholestatic rat liver

Hepatology (Baltimore, Md.), 2001-05, Vol.33 (5), p.1206-1216

2001

Volltextzugriff (PDF)

Long‐term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine

Hepatology (Baltimore, Md.), 1999-10, Vol.30 (4), p.870-875

1999

Volltextzugriff (PDF)

Perforation of the Colon: A Rare Complication of Hepatocellular Carcinoma

Acta radiologica (1987), 2006-07, Vol.47 (6), p.538-542

2006

Volltextzugriff (PDF)

Co-morbidities and risk for drug-drug-interactions in HCV GT 1 patients treated with elbasvir/grazoprevir from the German Hepatitis C Registry (DHC-R)

Zeitschrift für Gastroenterologie, 2018, Vol.56 (1), p.E2-E89

2018

Volltextzugriff (PDF)

Sustained responders have lower rates of liver-related events and a better quality of life and productivity compared with non-responders/relapsers after antiviral treatment of chronic hepatitis C

Zeitschrift für Gastroenterologie, 2013-01, Vol.51 (1)

2013

Volltextzugriff (PDF)

ANP preconditioning does not increase protection against experimental pancreatitis, observed after general anesthesia and jugular vein catheterization

Pancreas, 2004-03, Vol.28 (2), p.166-173

2004

Volltextzugriff (PDF)

Utilization of elbasvir/grazoprevir (EBR/GZR) and adoption of resistance associated substitutions (RAS) testing in real-world treatment of HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R)

Zeitschrift für Gastroenterologie, 2018, Vol.56 (8), p.e288-e289

2018

Volltextzugriff (PDF)

Sustained virologic responders have lower rates of liver-related events and a better quality of life and productivity compared with non-responders/relapsers after antiviral treatment of chronic hepatitis C

Zeitschrift für Gastroenterologie, 2012-08, Vol.50 (8)

2012

Volltextzugriff (PDF)

1 – 25 von 212

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(188)
Mit Volltextzugriff
(119)

Publikationsform

Sprache

Englisch
(176)
Deutsch
(80)

Erscheinungsjahr

n.n

Thema

Science & Technology
(85)
Life Sciences & Biomedicine
(79)
Animals
(61)
Male
(58)
Biological And Medical Sciences
(47)
Rats
(45)
Humans
(42)
Medical Sciences
(40)
Female
(30)
Gastroenterology & Hepatology
(29)
Middle Aged
(18)
Rats, Sprague-Dawley
(17)
Liver - Metabolism
(16)
Adult
(13)
Gastroenterology. Liver. Pancreas. Abdomen
(12)
Glutathione - Metabolism
(12)
Liver - Pathology
(12)
Reperfusion Injury - Prevention & Control
(12)
Liver - Blood Supply
(11)
Liver - Drug Effects
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver

P1137 TREATMENT OF CHRONIC HCV GENOTYPE 1 (G1) INFECTION WITH BOCEPREVIR IN GERMAN REAL-LIFE: HIGH EFFICACY TOGETHER WITH MODERATE TREATMENT DISCONTINUATION RATES IN TREATMENT-NAIVE PATIENTS

912 LEUKOCYTE DECLINE PREDICTS SUSTAINED VIROLOGIC RESPONSE IN PATIENTS UNDERGOING PEGINTERFERON alfa-2b/RIBAVIRIN TREATMENT OF CHRONIC HCV GENOTYPE 1 INFECTION

797 HIGH PREVALENCE OF CHRONIC HEPATITIS C IN 8009 PATIENTS WITH MIGRATION BACKGROUND LIVING IN GERMANY

1164 HEMOGLOBINE DECLINE DURING PEGINTERFERON ALFA-2B/RIBAVIRIN TREATMENT IN REAL-LIFE IS ASSOCIATED WITH FAVORABLE SVR RATES IN DIFFICULT-TO-TREAT PATIENTS WITH HCV GENOTYPE 1 INFECTION

1140 THYROID DYSFUNCTION INDUCED BY PEGINTERFERON ALFA-2B (PEG-2B)/RIBAVIRIN (RBV) IS A FAVORABLE PREDICTOR OF SVR IN DIFFICULT-TO-TREAT PATIENTS WITH HCV GENOTYPE 1 (G1) INFECTION

435 TREATMENT OF HCV GENOTYPE 3 (GT3)-INFECTION WITH PEG-IFN A-2B AND RIBAVIRIN (RBV): AGE RELATED DIFFERENCES IN SVR AND RELAPSE

Glutathione protects the rat liver against reperfusion injury after hypothermic preservation

305 TREATMENT-INDUCED ANEMIA PREDICTS SVR AMONG ALL HCV-GENOTYPES TREATED WITH PEG-IFNα-2B AND RIBAVIRIN: MARKED DIFFERENCES BETWEEN FEMALE AND MALE

GSH Attenuates Organ Injury and Improves Function after Transplantation of Fatty Livers

[677] CHOLESTASIS BUT NOT STEATOSIS POTENTIATES LIVER INJURY BY ACTIVATED KUPFFER CELLS: EVIDENCE FOR A ROLE FOR CYCLOOXYGENASE-2

Utilization of elbasvir/grazoprevir (EBR/GZR) and adoption of resistance associated substitutions (RAS) testing in real-world treatment of HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R)

THU-321 - Utilization of elbasvir/grazoprevir (EBR/GZR) and adoption of resistance associated substitutions (RAS) testing in real-world treatment of HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R)

Gender-dependent differences in the efficacy and safety of Boceprevir triple therapy in German real-life

Preservation injury of the liver : mechanisms and novel therapeutic strategies

Inverse correlation of serum bilirubin and alkaline phosphatase in fulminant Wilson's disease

Glutathione protects the rat liver against reperfusion injury after prolonged warm ischemia

Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C–dependent mechanisms in cholestatic rat liver

Long‐term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine

Perforation of the Colon: A Rare Complication of Hepatocellular Carcinoma

Co-morbidities and risk for drug-drug-interactions in HCV GT 1 patients treated with elbasvir/grazoprevir from the German Hepatitis C Registry (DHC-R)

Sustained responders have lower rates of liver-related events and a better quality of life and productivity compared with non-responders/relapsers after antiviral treatment of chronic hepatitis C

ANP preconditioning does not increase protection against experimental pancreatitis, observed after general anesthesia and jugular vein catheterization

Utilization of elbasvir/grazoprevir (EBR/GZR) and adoption of resistance associated substitutions (RAS) testing in real-world treatment of HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R)

Sustained virologic responders have lower rates of liver-related events and a better quality of life and productivity compared with non-responders/relapsers after antiviral treatment of chronic hepatitis C

Suchergebnisse filtern